Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Aidan Tomlinson"'
Autor:
Yu C. Yang, Severin Thompson, David Montgomery, Antonio J. Quiñones, Xing Wei, Benjamin Madej, Aidan Tomlinson, Nataliya T. Shifrin, Alexander McNamara, Ethan Ahler, Laura L. McDowell, Michael Flagella, John Setser, Stephanie Chang, Zhican Wang, Zhengping Wang, Jun Huang, Steve Ballmer, Shaong li, Andreas Buckl, Elena Koltun, Adrian Gill, Jingjing Jiang, Mallika Singh, Jacqueline A. Smith
Publikováno v:
Cancer Research. 83:1598-1598
KRASQ61H mutant cancers represent a significant unmet medical need and include common solid tumor histotypes such as non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC). Currently, there are no tar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5b4c8ac4c8666e1ef6d5a72a0c1f2d65
https://doi.org/10.1158/1538-7445.am2023-1598
https://doi.org/10.1158/1538-7445.am2023-1598
Autor:
Christopher J. Schulze, Jim Cregg, Kyle J. Seamon, Yu Chi Yang, Zhican Wang, Lindsay S. Garrenton, Alun Bermingham, John E. Knox, Aidan Tomlinson, Kang-Jye Chou, Shaoling Li, David P. Wildes, Mallika Singh, Elena S. Koltun, Adrian L. Gill, Robert J. Nichols, Jacqueline A. Smith
Publikováno v:
Cancer Research. 82:3598-3598
The clinical activity of KRASG12C(OFF) inhibitors has validated KRASG12C as an oncogenic driver in human cancers and demonstrated the power of targeting cysteine mutations with covalent inhibitors. A second oncogenic RAS cysteine mutation, KRASG13C,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a391fa7cfc38c6ad08db316050b88ca3
https://doi.org/10.1158/1538-7445.am2022-3598
https://doi.org/10.1158/1538-7445.am2022-3598